Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 7.5% – Time to Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shot up 7.5% during mid-day trading on Thursday . The company traded as high as $0.26 and last traded at $0.25. 33,566,019 shares were traded during trading, a decline of 48% from the average session volume of 64,815,828 shares. The stock had previously closed at $0.23.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a report on Friday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

The business has a 50-day moving average of $0.26 and a 200 day moving average of $0.30. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The company has a market cap of $44.01 million, a PE ratio of 0.00 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.